$0.91
5.50% yesterday
Nasdaq, Apr 04, 07:37 pm CET
ISIN
US04301G2012
Symbol
ARTL

Artelo Biosciences Inc Stock price

$0.92
-0.12 11.34% 1M
-0.20 17.72% 6M
-0.14 13.43% YTD
-0.61 40.07% 1Y
-6.13 86.98% 3Y
-12.54 93.18% 5Y
-68.83 98.68% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
+0.06 6.97%
ISIN
US04301G2012
Symbol
ARTL

Key metrics

Market capitalization $3.01m
Enterprise Value $770.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.05
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-10.11m
Free Cash Flow (TTM) Free Cash Flow $-8.23m
Cash position $2.34m
EPS (TTM) EPS $-3.05
P/E forward negative
Short interest 0.04%
Show more

Is Artelo Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Artelo Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Artelo Biosciences Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Artelo Biosciences Inc forecast:

Buy
100%

Financial data from Artelo Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.12 4.12
3% 3%
-
- Research and Development Expense 5.99 5.99
5% 5%
-
-10 -10
2% 2%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -10 -10
2% 2%
-
Net Profit -9.83 -9.83
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Artelo Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Artelo Biosciences Inc Stock News

Neutral
GlobeNewsWire
5 days ago
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, will be presenting at 12:30pm BST on April ...
Neutral
GlobeNewsWire
about one month ago
SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ende...
Neutral
GlobeNewsWire
about 2 months ago
SOLANA BEACH, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and...
More Artelo Biosciences Inc News

Company Profile

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

Head office United States
CEO Gregory Gorgas
Employees 6
Founded 2011
Website www.artelobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today